Skip to content
OpenCapital
Get started

Ventas VTR OM&R — NOI

Similar metrics at other companies

Welltower logo
WELLOutpatient Medical — Net Operating Income
$53.3M-63.6%
Healthpeak Properties logo
DOCOutpatient medical — Net Operating Income From Continuing Operations
$208.85M-0.2%
COPT Defense Properties logo
CDPOther — NOI
$8.15M-13.9%
Piedmont Office Realty Trust logo
PDMNew York — NOI
$7.79M+2.9%
Piedmont Office Realty Trust logo
PDMOrlando — NOI
$12M+30.3%
InvenTrust Properties logo
IVTReportable Segment — NOI
$56.42M+8.8%

Other financials

Income statement

See full
Revenue$1.7B+22.0%
Net income$59.0M+22.1%
EPS (diluted)$0.11+10.0%

Balance sheet

See full
Cash & equivalents$183.6M+0.7%
Total debt$12.7B-1.5%
Total equity$13.1B+14.4%
Total assets$27.7B+6.4%

Cash flow

See full
Operating cash flow$394.6M+22.9%

Valuation

See full
Market cap$42.51B+50.8%
Enterprise value$55.05B+34.5%
P/E156.2×-32.7×
P/S6.9×+1.4×

Profitability

See full
Net margin4.4%+1.5pp
FCF margin33.1%—

Returns & leverage

See full
Return on equity2.2%+0.8pp
Debt / equity1×-0.2×

Where this comes from

Reported directly by Ventas in its filing.

Tagged under the XBRL concept vtr:NetOperatingIncome.

The official record: Ventas’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ventas's om&r — noi.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ventas's OM&R — NOI?
Ventas (VTR) reported OM&R — NOI of $150.6M in Q1 2026.
How has Ventas's OM&R — NOI changed year-over-year?
Ventas's OM&R — NOI increased by 3.1% year-over-year, from $146.04M to $150.6M.
What is the long-term trend for Ventas's OM&R — NOI?
Over 4 years (2021 to 2025), Ventas's OM&R — NOI has grown at a 2.1% compound annual growth rate (CAGR), from $543.88M to $590.17M.
What does OM&R — NOI mean?
Net Operating Income (NOI) generated specifically by the Outpatient Medical and Research (OM&R) real estate portfolio. This metric represents the profitability of these properties after deducting operating expenses from property revenues, excluding corporate-level costs and interest. It serves as a primary indicator of the operational performance and cash flow generation of the company's medical office and life science assets.